

Phase I Clinical Trial Demonstrates Bod's Patented CBD Wafer Superiority

- **Successful completion of Phase I Clinical trial validates Bod's sublingual cannabis wafer commercialisation prospects**
- **Wafer shown to be safe for human consumption – Results revealed excellent tolerability characteristics**
- **Clinically supported safety data is an important requirement for potential prescribers - provides significant added advantage as Bod engages European distribution partners**
- **Wafer proven to absorb significantly faster than the oil and TGA approved competitor product**
- **Superior bioavailability could potentially benefit patients using cannabis as it could provide faster relief from symptoms**
- **Validates superiority of Bod's CBD extract ECs315 and the unique delivery method (patent protected and exclusive)**
- **Bod to review and finalise commercialisation options and determine partners that may want to target specific indications for further investigation.**

Sydney, Australia – 26 March 2019: Developer and distributor of natural, evidence-based health products with a focus on medicinal cannabis, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) advised that it has completed the experimental aspect of the Phase I Clinical Trial of its sublingual cannabis wafer. The trial was a phase I, open label, randomised, placebo controlled, four-way crossover study to determine the safety, tolerability, and pharmacokinetics of ECs315 administered as a single or multiple sublingual wafer and oil to healthy volunteers (CT-2018-CTN-00462-1).

Bod received preliminary trial results, based on 24 healthy volunteers which highlights the superiority of its proprietary CBD extract ECs315 and patented wafer delivery method. Both the ECs315 Oil extract and sublingual wafer have been deemed safe for human consumption showing excellent tolerability characteristics.

It was also shown that the CBD from the wafer achieved faster absorption rates than in oil form and compared to another competitor product. This superior bioavailability of the wafer could be of particular benefit to patients using cannabis as they could have faster relief from their symptoms.

Bod Australia CEO Jo Patterson said: “Results from the Phase I Clinical Trial of Bod's cannabis wafer validate the superiority of our product and the tremendous opportunity Bod has as a developer of medicinal cannabis products.

“We have effectively shown that by administering CBD through a sublingual wafer, it is absorbed faster than CBD in oil and compares more favourably to a registered product available in Australia and overseas.

“Bod is now progressing regulatory, commercialisation and export activities with all advancing well. This will underpin a planned scale up in production.”

These results have validated Bod's strategy to introduce a novel, effective delivery method of CBD products. The Company has now clearly demonstrated that its sublingual wafer can be used in place of CBD oil and deliver a fixed dose of a CBD in an efficient and consistent manner.

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 69.4m
 Market Capitalisation ~\$23.2m

BOARD & MANAGEMENT

Mr George Livery
 Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Stephen Thompson
 Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Simon Taylor
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

Bod can now also leverage safety data from this trial for its current medicinal cannabis product suite. The Company is also exploring several opportunities to further utilise the delivery method by suspending additional products into the wafer format.

Safety data on Bods ECs315 and patented sublingual wafer will greatly assist penetration in markets including Europe and the Americas, both with significant potential sales upside. Initial export orders of two wafer strengths are expected following relevant approvals. Products will be exported under Bod's licence for export granted November 2018 (refer ASX announcement: 20 November 2018).

The clinical trial report will be finalised in May and Bod expects the outcomes to be published in medical journals and research reports thereafter.

-ENDS-

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia's largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538